nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—FGFR3—colon cancer	0.333	0.622	CbGaD
Ponatinib—SRC—colon cancer	0.168	0.314	CbGaD
Ponatinib—ABCB11—Vincristine—colon cancer	0.0443	0.229	CbGbCtD
Ponatinib—ABCB1—colon cancer	0.0344	0.0642	CbGaD
Ponatinib—ABCG2—Irinotecan—colon cancer	0.0241	0.125	CbGbCtD
Ponatinib—ABCG2—Fluorouracil—colon cancer	0.0231	0.12	CbGbCtD
Ponatinib—ABCG2—Vincristine—colon cancer	0.0211	0.109	CbGbCtD
Ponatinib—CYP3A5—Irinotecan—colon cancer	0.0133	0.0691	CbGbCtD
Ponatinib—ABCG2—Methotrexate—colon cancer	0.0127	0.066	CbGbCtD
Ponatinib—CYP2C8—Fluorouracil—colon cancer	0.0123	0.0637	CbGbCtD
Ponatinib—CYP3A5—Vincristine—colon cancer	0.0117	0.0604	CbGbCtD
Ponatinib—ABCB1—Irinotecan—colon cancer	0.00869	0.0449	CbGbCtD
Ponatinib—ABCB1—Vincristine—colon cancer	0.00759	0.0393	CbGbCtD
Ponatinib—CYP3A4—Irinotecan—colon cancer	0.0052	0.0269	CbGbCtD
Ponatinib—ABCB1—Methotrexate—colon cancer	0.0046	0.0238	CbGbCtD
Ponatinib—CYP3A4—Vincristine—colon cancer	0.00455	0.0235	CbGbCtD
Ponatinib—ABCB11—bile—colon cancer	0.00416	0.0621	CbGeAlD
Ponatinib—KIT—myenteric nerve plexus—colon cancer	0.00406	0.0605	CbGeAlD
Ponatinib—KDR—umbilical vein—colon cancer	0.00214	0.0319	CbGeAlD
Ponatinib—FGFR4—embryo—colon cancer	0.0016	0.0238	CbGeAlD
Ponatinib—Nilotinib—CA7—colon cancer	0.00159	0.373	CrCbGaD
Ponatinib—FGFR4—Vinblastine—Vincristine—colon cancer	0.00138	0.565	CbGdCrCtD
Ponatinib—Imatinib—CA7—colon cancer	0.00132	0.311	CrCbGaD
Ponatinib—TEK—endothelium—colon cancer	0.00124	0.0185	CbGeAlD
Ponatinib—FGFR4—renal system—colon cancer	0.00121	0.018	CbGeAlD
Ponatinib—TEK—blood vessel—colon cancer	0.00115	0.0171	CbGeAlD
Ponatinib—SRC—endothelium—colon cancer	0.0011	0.0165	CbGeAlD
Ponatinib—FGFR3—embryo—colon cancer	0.00109	0.0162	CbGeAlD
Ponatinib—ABL1—Topotecan—Irinotecan—colon cancer	0.00106	0.435	CbGdCrCtD
Ponatinib—SRC—blood vessel—colon cancer	0.00102	0.0152	CbGeAlD
Ponatinib—KDR—endothelium—colon cancer	0.00101	0.0151	CbGeAlD
Ponatinib—Nilotinib—BRAF—colon cancer	0.001	0.236	CrCbGaD
Ponatinib—FGFR4—digestive system—colon cancer	0.00099	0.0148	CbGeAlD
Ponatinib—PDGFRA—gall bladder—colon cancer	0.000976	0.0146	CbGeAlD
Ponatinib—KDR—blood vessel—colon cancer	0.000936	0.014	CbGeAlD
Ponatinib—KIT—endothelium—colon cancer	0.000899	0.0134	CbGeAlD
Ponatinib—FGFR3—epithelium—colon cancer	0.000888	0.0132	CbGeAlD
Ponatinib—KIT—blood vessel—colon cancer	0.000829	0.0124	CbGeAlD
Ponatinib—FGFR3—renal system—colon cancer	0.000824	0.0123	CbGeAlD
Ponatinib—KIT—gall bladder—colon cancer	0.00078	0.0116	CbGeAlD
Ponatinib—RET—embryo—colon cancer	0.00075	0.0112	CbGeAlD
Ponatinib—FGFR4—liver—colon cancer	0.000738	0.011	CbGeAlD
Ponatinib—BCR—renal system—colon cancer	0.000713	0.0106	CbGeAlD
Ponatinib—FGFR2—embryo—colon cancer	0.000713	0.0106	CbGeAlD
Ponatinib—LYN—lymphoid tissue—colon cancer	0.000688	0.0103	CbGeAlD
Ponatinib—TEK—embryo—colon cancer	0.000683	0.0102	CbGeAlD
Ponatinib—PDGFRA—embryo—colon cancer	0.000619	0.00923	CbGeAlD
Ponatinib—RET—epithelium—colon cancer	0.000612	0.00913	CbGeAlD
Ponatinib—SRC—embryo—colon cancer	0.000607	0.00905	CbGeAlD
Ponatinib—BCR—lymphoid tissue—colon cancer	0.000592	0.00883	CbGeAlD
Ponatinib—FLT3—lymphoid tissue—colon cancer	0.000588	0.00877	CbGeAlD
Ponatinib—FGFR2—epithelium—colon cancer	0.000581	0.00867	CbGeAlD
Ponatinib—RET—renal system—colon cancer	0.000568	0.00847	CbGeAlD
Ponatinib—FGFR4—lymph node—colon cancer	0.000566	0.00844	CbGeAlD
Ponatinib—FGFR2—smooth muscle tissue—colon cancer	0.00056	0.00836	CbGeAlD
Ponatinib—KDR—embryo—colon cancer	0.000558	0.00833	CbGeAlD
Ponatinib—TEK—epithelium—colon cancer	0.000557	0.00831	CbGeAlD
Ponatinib—FGFR2—renal system—colon cancer	0.000539	0.00804	CbGeAlD
Ponatinib—BCR—bone marrow—colon cancer	0.000539	0.00804	CbGeAlD
Ponatinib—TEK—smooth muscle tissue—colon cancer	0.000537	0.00801	CbGeAlD
Ponatinib—FLT3—bone marrow—colon cancer	0.000535	0.00798	CbGeAlD
Ponatinib—TEK—renal system—colon cancer	0.000517	0.00771	CbGeAlD
Ponatinib—BCR—vagina—colon cancer	0.000516	0.0077	CbGeAlD
Ponatinib—LYN—liver—colon cancer	0.000506	0.00755	CbGeAlD
Ponatinib—FGFR3—liver—colon cancer	0.000503	0.00751	CbGeAlD
Ponatinib—SRC—epithelium—colon cancer	0.000495	0.00739	CbGeAlD
Ponatinib—KIT—embryo—colon cancer	0.000495	0.00738	CbGeAlD
Ponatinib—PDGFRA—smooth muscle tissue—colon cancer	0.000487	0.00726	CbGeAlD
Ponatinib—SRC—smooth muscle tissue—colon cancer	0.000477	0.00712	CbGeAlD
Ponatinib—RET—lymphoid tissue—colon cancer	0.000471	0.00703	CbGeAlD
Ponatinib—PDGFRA—renal system—colon cancer	0.000468	0.00699	CbGeAlD
Ponatinib—RET—digestive system—colon cancer	0.000466	0.00694	CbGeAlD
Ponatinib—FGFR1—vagina—colon cancer	0.000459	0.00685	CbGeAlD
Ponatinib—SRC—renal system—colon cancer	0.000459	0.00685	CbGeAlD
Ponatinib—KDR—epithelium—colon cancer	0.000456	0.0068	CbGeAlD
Ponatinib—ABCB11—digestive system—colon cancer	0.000455	0.00678	CbGeAlD
Ponatinib—FGFR2—digestive system—colon cancer	0.000442	0.0066	CbGeAlD
Ponatinib—KDR—smooth muscle tissue—colon cancer	0.000439	0.00655	CbGeAlD
Ponatinib—BCR—liver—colon cancer	0.000436	0.0065	CbGeAlD
Ponatinib—FLT3—liver—colon cancer	0.000433	0.00645	CbGeAlD
Ponatinib—ABL1—embryo—colon cancer	0.000431	0.00642	CbGeAlD
Ponatinib—TEK—lymphoid tissue—colon cancer	0.000429	0.0064	CbGeAlD
Ponatinib—LCK—bone marrow—colon cancer	0.000429	0.0064	CbGeAlD
Ponatinib—KDR—renal system—colon cancer	0.000423	0.0063	CbGeAlD
Ponatinib—LCK—vagina—colon cancer	0.000411	0.00613	CbGeAlD
Ponatinib—KIT—epithelium—colon cancer	0.000404	0.00602	CbGeAlD
Ponatinib—KIT—smooth muscle tissue—colon cancer	0.000389	0.0058	CbGeAlD
Ponatinib—PDGFRA—lymphoid tissue—colon cancer	0.000389	0.0058	CbGeAlD
Ponatinib—FGFR1—liver—colon cancer	0.000388	0.00578	CbGeAlD
Ponatinib—PDGFRA—digestive system—colon cancer	0.000384	0.00573	CbGeAlD
Ponatinib—SRC—lymphoid tissue—colon cancer	0.000381	0.00569	CbGeAlD
Ponatinib—SRC—digestive system—colon cancer	0.000377	0.00562	CbGeAlD
Ponatinib—KIT—renal system—colon cancer	0.000374	0.00559	CbGeAlD
Ponatinib—KDR—lymphoid tissue—colon cancer	0.000351	0.00523	CbGeAlD
Ponatinib—LCK—liver—colon cancer	0.000347	0.00517	CbGeAlD
Ponatinib—KDR—digestive system—colon cancer	0.000347	0.00517	CbGeAlD
Ponatinib—PDGFRA—vagina—colon cancer	0.000339	0.00506	CbGeAlD
Ponatinib—ABCB11—liver—colon cancer	0.000339	0.00505	CbGeAlD
Ponatinib—ABL1—smooth muscle tissue—colon cancer	0.000339	0.00505	CbGeAlD
Ponatinib—BCR—lymph node—colon cancer	0.000334	0.00498	CbGeAlD
Ponatinib—FLT3—lymph node—colon cancer	0.000332	0.00495	CbGeAlD
Ponatinib—FGFR2—liver—colon cancer	0.00033	0.00492	CbGeAlD
Ponatinib—ABL1—renal system—colon cancer	0.000326	0.00486	CbGeAlD
Ponatinib—KDR—bone marrow—colon cancer	0.00032	0.00477	CbGeAlD
Ponatinib—TEK—liver—colon cancer	0.000316	0.00471	CbGeAlD
Ponatinib—KIT—lymphoid tissue—colon cancer	0.000311	0.00464	CbGeAlD
Ponatinib—KIT—digestive system—colon cancer	0.000307	0.00458	CbGeAlD
Ponatinib—KDR—vagina—colon cancer	0.000306	0.00457	CbGeAlD
Ponatinib—FGFR1—lymph node—colon cancer	0.000297	0.00443	CbGeAlD
Ponatinib—PDGFRA—liver—colon cancer	0.000286	0.00427	CbGeAlD
Ponatinib—KIT—bone marrow—colon cancer	0.000283	0.00422	CbGeAlD
Ponatinib—SRC—liver—colon cancer	0.000281	0.00419	CbGeAlD
Ponatinib—KIT—vagina—colon cancer	0.000271	0.00405	CbGeAlD
Ponatinib—ABL1—lymphoid tissue—colon cancer	0.000271	0.00404	CbGeAlD
Ponatinib—ABL1—digestive system—colon cancer	0.000267	0.00399	CbGeAlD
Ponatinib—LCK—lymph node—colon cancer	0.000266	0.00397	CbGeAlD
Ponatinib—RET—lymph node—colon cancer	0.000266	0.00397	CbGeAlD
Ponatinib—KDR—liver—colon cancer	0.000258	0.00385	CbGeAlD
Ponatinib—ABL1—bone marrow—colon cancer	0.000246	0.00368	CbGeAlD
Ponatinib—TEK—lymph node—colon cancer	0.000242	0.00361	CbGeAlD
Ponatinib—ABL1—vagina—colon cancer	0.000236	0.00352	CbGeAlD
Ponatinib—KIT—liver—colon cancer	0.000229	0.00341	CbGeAlD
Ponatinib—ABCB1—blood vessel—colon cancer	0.000225	0.00335	CbGeAlD
Ponatinib—PDGFRA—lymph node—colon cancer	0.000219	0.00327	CbGeAlD
Ponatinib—SRC—lymph node—colon cancer	0.000215	0.00321	CbGeAlD
Ponatinib—CYP2C8—renal system—colon cancer	0.000211	0.00315	CbGeAlD
Ponatinib—ABL1—liver—colon cancer	0.000199	0.00297	CbGeAlD
Ponatinib—KDR—lymph node—colon cancer	0.000198	0.00295	CbGeAlD
Ponatinib—CYP3A5—renal system—colon cancer	0.000191	0.00285	CbGeAlD
Ponatinib—Nilotinib—ABCB1—colon cancer	0.000185	0.0436	CrCbGaD
Ponatinib—KIT—lymph node—colon cancer	0.000175	0.00262	CbGeAlD
Ponatinib—Hypoaesthesia—Fluorouracil—colon cancer	0.000167	0.002	CcSEcCtD
Ponatinib—Migraine—Capecitabine—colon cancer	0.000167	0.00199	CcSEcCtD
Ponatinib—Skin exfoliation—Methotrexate—colon cancer	0.000166	0.00198	CcSEcCtD
Ponatinib—Face oedema—Capecitabine—colon cancer	0.000164	0.00196	CcSEcCtD
Ponatinib—Angiopathy—Vincristine—colon cancer	0.000163	0.00195	CcSEcCtD
Ponatinib—Flushing—Irinotecan—colon cancer	0.000163	0.00194	CcSEcCtD
Ponatinib—Cardiac disorder—Irinotecan—colon cancer	0.000163	0.00194	CcSEcCtD
Ponatinib—Mediastinal disorder—Vincristine—colon cancer	0.000162	0.00194	CcSEcCtD
Ponatinib—Alopecia—Vincristine—colon cancer	0.000159	0.0019	CcSEcCtD
Ponatinib—Angiopathy—Irinotecan—colon cancer	0.000159	0.0019	CcSEcCtD
Ponatinib—Blood creatinine increased—Capecitabine—colon cancer	0.000159	0.0019	CcSEcCtD
Ponatinib—Mediastinal disorder—Irinotecan—colon cancer	0.000158	0.00189	CcSEcCtD
Ponatinib—Dehydration—Capecitabine—colon cancer	0.000158	0.00188	CcSEcCtD
Ponatinib—Mental disorder—Vincristine—colon cancer	0.000158	0.00188	CcSEcCtD
Ponatinib—Chills—Irinotecan—colon cancer	0.000157	0.00188	CcSEcCtD
Ponatinib—Ecchymosis—Methotrexate—colon cancer	0.000157	0.00188	CcSEcCtD
Ponatinib—Arrhythmia—Irinotecan—colon cancer	0.000157	0.00187	CcSEcCtD
Ponatinib—CYP3A5—digestive system—colon cancer	0.000157	0.00233	CbGeAlD
Ponatinib—Dry skin—Capecitabine—colon cancer	0.000155	0.00186	CcSEcCtD
Ponatinib—ABCG2—bone marrow—colon cancer	0.000155	0.00232	CbGeAlD
Ponatinib—Alopecia—Irinotecan—colon cancer	0.000155	0.00185	CcSEcCtD
Ponatinib—Imatinib—ABCB1—colon cancer	0.000155	0.0363	CrCbGaD
Ponatinib—Hypokalaemia—Capecitabine—colon cancer	0.000154	0.00184	CcSEcCtD
Ponatinib—Breast disorder—Capecitabine—colon cancer	0.000153	0.00183	CcSEcCtD
Ponatinib—CYP2C8—vagina—colon cancer	0.000153	0.00228	CbGeAlD
Ponatinib—ABL1—lymph node—colon cancer	0.000153	0.00228	CbGeAlD
Ponatinib—Aspartate aminotransferase increased—Capecitabine—colon cancer	0.000153	0.00182	CcSEcCtD
Ponatinib—Nasopharyngitis—Capecitabine—colon cancer	0.000152	0.00181	CcSEcCtD
Ponatinib—Back pain—Vincristine—colon cancer	0.000152	0.00181	CcSEcCtD
Ponatinib—Sepsis—Methotrexate—colon cancer	0.000151	0.0018	CcSEcCtD
Ponatinib—Arrhythmia—Fluorouracil—colon cancer	0.00015	0.00179	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Capecitabine—colon cancer	0.00015	0.00179	CcSEcCtD
Ponatinib—ABCG2—vagina—colon cancer	0.000149	0.00222	CbGeAlD
Ponatinib—Alopecia—Fluorouracil—colon cancer	0.000148	0.00177	CcSEcCtD
Ponatinib—Back pain—Irinotecan—colon cancer	0.000148	0.00176	CcSEcCtD
Ponatinib—Abdominal distension—Capecitabine—colon cancer	0.000148	0.00176	CcSEcCtD
Ponatinib—Muscle spasms—Irinotecan—colon cancer	0.000147	0.00175	CcSEcCtD
Ponatinib—Erythema—Fluorouracil—colon cancer	0.000146	0.00175	CcSEcCtD
Ponatinib—Anaemia—Vincristine—colon cancer	0.000145	0.00173	CcSEcCtD
Ponatinib—CYP3A4—renal system—colon cancer	0.000143	0.00214	CbGeAlD
Ponatinib—Angina pectoris—Capecitabine—colon cancer	0.000143	0.00171	CcSEcCtD
Ponatinib—Anaemia—Irinotecan—colon cancer	0.000141	0.00168	CcSEcCtD
Ponatinib—CYP2D6—renal system—colon cancer	0.000141	0.0021	CbGeAlD
Ponatinib—Abdominal discomfort—Capecitabine—colon cancer	0.000141	0.00168	CcSEcCtD
Ponatinib—Leukopenia—Vincristine—colon cancer	0.00014	0.00168	CcSEcCtD
Ponatinib—Pancytopenia—Capecitabine—colon cancer	0.000139	0.00166	CcSEcCtD
Ponatinib—CYP3A5—vagina—colon cancer	0.000138	0.00206	CbGeAlD
Ponatinib—Vision blurred—Fluorouracil—colon cancer	0.000138	0.00164	CcSEcCtD
Ponatinib—Neutropenia—Capecitabine—colon cancer	0.000137	0.00164	CcSEcCtD
Ponatinib—Leukopenia—Irinotecan—colon cancer	0.000137	0.00163	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Capecitabine—colon cancer	0.000136	0.00163	CcSEcCtD
Ponatinib—Hypertension—Vincristine—colon cancer	0.000135	0.00162	CcSEcCtD
Ponatinib—Anaemia—Fluorouracil—colon cancer	0.000135	0.00161	CcSEcCtD
Ponatinib—ABCB1—embryo—colon cancer	0.000134	0.002	CbGeAlD
Ponatinib—Dermatitis exfoliative—Methotrexate—colon cancer	0.000134	0.0016	CcSEcCtD
Ponatinib—Myalgia—Vincristine—colon cancer	0.000133	0.00159	CcSEcCtD
Ponatinib—Cough—Irinotecan—colon cancer	0.000133	0.00159	CcSEcCtD
Ponatinib—Weight decreased—Capecitabine—colon cancer	0.000133	0.00158	CcSEcCtD
Ponatinib—Hyperglycaemia—Capecitabine—colon cancer	0.000132	0.00158	CcSEcCtD
Ponatinib—Hypertension—Irinotecan—colon cancer	0.000132	0.00157	CcSEcCtD
Ponatinib—Pneumonia—Capecitabine—colon cancer	0.000131	0.00157	CcSEcCtD
Ponatinib—Leukopenia—Fluorouracil—colon cancer	0.000131	0.00156	CcSEcCtD
Ponatinib—Infestation—Capecitabine—colon cancer	0.000131	0.00156	CcSEcCtD
Ponatinib—Infestation NOS—Capecitabine—colon cancer	0.000131	0.00156	CcSEcCtD
Ponatinib—CYP2C8—liver—colon cancer	0.000129	0.00193	CbGeAlD
Ponatinib—Acute coronary syndrome—Capecitabine—colon cancer	0.000129	0.00154	CcSEcCtD
Ponatinib—Lethargy—Methotrexate—colon cancer	0.000129	0.00154	CcSEcCtD
Ponatinib—Cerebrovascular accident—Methotrexate—colon cancer	0.000129	0.00154	CcSEcCtD
Ponatinib—Myocardial infarction—Capecitabine—colon cancer	0.000128	0.00153	CcSEcCtD
Ponatinib—Neuropathy peripheral—Capecitabine—colon cancer	0.000128	0.00153	CcSEcCtD
Ponatinib—Oedema—Vincristine—colon cancer	0.000128	0.00153	CcSEcCtD
Ponatinib—Stomatitis—Capecitabine—colon cancer	0.000127	0.00152	CcSEcCtD
Ponatinib—Jaundice—Capecitabine—colon cancer	0.000127	0.00152	CcSEcCtD
Ponatinib—Infection—Vincristine—colon cancer	0.000127	0.00152	CcSEcCtD
Ponatinib—Urinary tract infection—Capecitabine—colon cancer	0.000127	0.00152	CcSEcCtD
Ponatinib—ABCG2—liver—colon cancer	0.000126	0.00187	CbGeAlD
Ponatinib—Nervous system disorder—Vincristine—colon cancer	0.000125	0.0015	CcSEcCtD
Ponatinib—Thrombocytopenia—Vincristine—colon cancer	0.000125	0.0015	CcSEcCtD
Ponatinib—Oedema—Irinotecan—colon cancer	0.000125	0.00149	CcSEcCtD
Ponatinib—Myalgia—Fluorouracil—colon cancer	0.000124	0.00149	CcSEcCtD
Ponatinib—Infection—Irinotecan—colon cancer	0.000124	0.00148	CcSEcCtD
Ponatinib—Hyperhidrosis—Vincristine—colon cancer	0.000124	0.00148	CcSEcCtD
Ponatinib—Hepatobiliary disease—Capecitabine—colon cancer	0.000124	0.00148	CcSEcCtD
Ponatinib—Epistaxis—Capecitabine—colon cancer	0.000123	0.00147	CcSEcCtD
Ponatinib—Nervous system disorder—Irinotecan—colon cancer	0.000122	0.00146	CcSEcCtD
Ponatinib—Thrombocytopenia—Irinotecan—colon cancer	0.000122	0.00146	CcSEcCtD
Ponatinib—Hyperhidrosis—Irinotecan—colon cancer	0.00012	0.00144	CcSEcCtD
Ponatinib—Oedema—Fluorouracil—colon cancer	0.000119	0.00142	CcSEcCtD
Ponatinib—Infection—Fluorouracil—colon cancer	0.000118	0.00142	CcSEcCtD
Ponatinib—Haemoglobin—Capecitabine—colon cancer	0.000118	0.00141	CcSEcCtD
Ponatinib—CYP3A4—digestive system—colon cancer	0.000117	0.00175	CbGeAlD
Ponatinib—Haemorrhage—Capecitabine—colon cancer	0.000117	0.0014	CcSEcCtD
Ponatinib—Nervous system disorder—Fluorouracil—colon cancer	0.000117	0.0014	CcSEcCtD
Ponatinib—Thrombocytopenia—Fluorouracil—colon cancer	0.000117	0.00139	CcSEcCtD
Ponatinib—Hypoaesthesia—Capecitabine—colon cancer	0.000117	0.00139	CcSEcCtD
Ponatinib—CYP3A5—liver—colon cancer	0.000117	0.00174	CbGeAlD
Ponatinib—Musculoskeletal discomfort—Vincristine—colon cancer	0.000117	0.00139	CcSEcCtD
Ponatinib—Insomnia—Vincristine—colon cancer	0.000116	0.00138	CcSEcCtD
Ponatinib—CYP2D6—digestive system—colon cancer	0.000116	0.00172	CbGeAlD
Ponatinib—Oedema peripheral—Capecitabine—colon cancer	0.000116	0.00138	CcSEcCtD
Ponatinib—Connective tissue disorder—Capecitabine—colon cancer	0.000115	0.00138	CcSEcCtD
Ponatinib—Paraesthesia—Vincristine—colon cancer	0.000115	0.00137	CcSEcCtD
Ponatinib—Breast disorder—Methotrexate—colon cancer	0.000114	0.00136	CcSEcCtD
Ponatinib—Visual impairment—Capecitabine—colon cancer	0.000113	0.00135	CcSEcCtD
Ponatinib—Insomnia—Irinotecan—colon cancer	0.000113	0.00135	CcSEcCtD
Ponatinib—Paraesthesia—Irinotecan—colon cancer	0.000112	0.00134	CcSEcCtD
Ponatinib—Decreased appetite—Vincristine—colon cancer	0.000111	0.00133	CcSEcCtD
Ponatinib—Dyspnoea—Irinotecan—colon cancer	0.000111	0.00133	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Vincristine—colon cancer	0.00011	0.00132	CcSEcCtD
Ponatinib—Fatigue—Vincristine—colon cancer	0.00011	0.00132	CcSEcCtD
Ponatinib—Eye disorder—Capecitabine—colon cancer	0.00011	0.00131	CcSEcCtD
Ponatinib—Dyspepsia—Irinotecan—colon cancer	0.00011	0.00131	CcSEcCtD
Ponatinib—Constipation—Vincristine—colon cancer	0.000109	0.00131	CcSEcCtD
Ponatinib—Pain—Vincristine—colon cancer	0.000109	0.00131	CcSEcCtD
Ponatinib—ABCB1—epithelium—colon cancer	0.000109	0.00163	CbGeAlD
Ponatinib—Flushing—Capecitabine—colon cancer	0.000109	0.0013	CcSEcCtD
Ponatinib—Cardiac disorder—Capecitabine—colon cancer	0.000109	0.0013	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000109	0.0013	CcSEcCtD
Ponatinib—Decreased appetite—Irinotecan—colon cancer	0.000108	0.00129	CcSEcCtD
Ponatinib—Insomnia—Fluorouracil—colon cancer	0.000108	0.00129	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Irinotecan—colon cancer	0.000108	0.00128	CcSEcCtD
Ponatinib—Fatigue—Irinotecan—colon cancer	0.000107	0.00128	CcSEcCtD
Ponatinib—Paraesthesia—Fluorouracil—colon cancer	0.000107	0.00128	CcSEcCtD
Ponatinib—Pancreatitis—Methotrexate—colon cancer	0.000107	0.00128	CcSEcCtD
Ponatinib—Pain—Irinotecan—colon cancer	0.000106	0.00127	CcSEcCtD
Ponatinib—Constipation—Irinotecan—colon cancer	0.000106	0.00127	CcSEcCtD
Ponatinib—Angiopathy—Capecitabine—colon cancer	0.000106	0.00127	CcSEcCtD
Ponatinib—Dyspnoea—Fluorouracil—colon cancer	0.000106	0.00127	CcSEcCtD
Ponatinib—Mediastinal disorder—Capecitabine—colon cancer	0.000106	0.00126	CcSEcCtD
Ponatinib—Chills—Capecitabine—colon cancer	0.000105	0.00126	CcSEcCtD
Ponatinib—Dyspepsia—Fluorouracil—colon cancer	0.000105	0.00125	CcSEcCtD
Ponatinib—Arrhythmia—Capecitabine—colon cancer	0.000105	0.00125	CcSEcCtD
Ponatinib—Abdominal discomfort—Methotrexate—colon cancer	0.000105	0.00125	CcSEcCtD
Ponatinib—Gastrointestinal pain—Vincristine—colon cancer	0.000105	0.00125	CcSEcCtD
Ponatinib—Decreased appetite—Fluorouracil—colon cancer	0.000104	0.00124	CcSEcCtD
Ponatinib—Alopecia—Capecitabine—colon cancer	0.000104	0.00124	CcSEcCtD
Ponatinib—Pancytopenia—Methotrexate—colon cancer	0.000104	0.00124	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000103	0.00123	CcSEcCtD
Ponatinib—Mental disorder—Capecitabine—colon cancer	0.000103	0.00123	CcSEcCtD
Ponatinib—Malnutrition—Capecitabine—colon cancer	0.000102	0.00122	CcSEcCtD
Ponatinib—Erythema—Capecitabine—colon cancer	0.000102	0.00122	CcSEcCtD
Ponatinib—Neutropenia—Methotrexate—colon cancer	0.000102	0.00122	CcSEcCtD
Ponatinib—Pain—Fluorouracil—colon cancer	0.000102	0.00122	CcSEcCtD
Ponatinib—Gastrointestinal pain—Irinotecan—colon cancer	0.000102	0.00122	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Methotrexate—colon cancer	0.000101	0.00121	CcSEcCtD
Ponatinib—ABCB1—renal system—colon cancer	0.000101	0.00151	CbGeAlD
Ponatinib—Abdominal pain—Vincristine—colon cancer	0.000101	0.00121	CcSEcCtD
Ponatinib—Body temperature increased—Vincristine—colon cancer	0.000101	0.00121	CcSEcCtD
Ponatinib—Erectile dysfunction—Methotrexate—colon cancer	0.0001	0.0012	CcSEcCtD
Ponatinib—Back pain—Capecitabine—colon cancer	9.88e-05	0.00118	CcSEcCtD
Ponatinib—Body temperature increased—Irinotecan—colon cancer	9.84e-05	0.00118	CcSEcCtD
Ponatinib—Abdominal pain—Irinotecan—colon cancer	9.84e-05	0.00118	CcSEcCtD
Ponatinib—Muscle spasms—Capecitabine—colon cancer	9.82e-05	0.00117	CcSEcCtD
Ponatinib—Pneumonia—Methotrexate—colon cancer	9.79e-05	0.00117	CcSEcCtD
Ponatinib—Infestation NOS—Methotrexate—colon cancer	9.73e-05	0.00116	CcSEcCtD
Ponatinib—Infestation—Methotrexate—colon cancer	9.73e-05	0.00116	CcSEcCtD
Ponatinib—ABCG2—lymph node—colon cancer	9.63e-05	0.00144	CbGeAlD
Ponatinib—Vision blurred—Capecitabine—colon cancer	9.62e-05	0.00115	CcSEcCtD
Ponatinib—Stomatitis—Methotrexate—colon cancer	9.48e-05	0.00113	CcSEcCtD
Ponatinib—Anaemia—Capecitabine—colon cancer	9.44e-05	0.00113	CcSEcCtD
Ponatinib—Body temperature increased—Fluorouracil—colon cancer	9.43e-05	0.00113	CcSEcCtD
Ponatinib—Hepatobiliary disease—Methotrexate—colon cancer	9.2e-05	0.0011	CcSEcCtD
Ponatinib—Epistaxis—Methotrexate—colon cancer	9.18e-05	0.0011	CcSEcCtD
Ponatinib—Asthenia—Vincristine—colon cancer	9.17e-05	0.0011	CcSEcCtD
Ponatinib—Leukopenia—Capecitabine—colon cancer	9.14e-05	0.00109	CcSEcCtD
Ponatinib—Asthenia—Irinotecan—colon cancer	8.93e-05	0.00107	CcSEcCtD
Ponatinib—Cough—Capecitabine—colon cancer	8.91e-05	0.00106	CcSEcCtD
Ponatinib—Hypertension—Capecitabine—colon cancer	8.82e-05	0.00105	CcSEcCtD
Ponatinib—Haemoglobin—Methotrexate—colon cancer	8.78e-05	0.00105	CcSEcCtD
Ponatinib—CYP3A4—liver—colon cancer	8.75e-05	0.00131	CbGeAlD
Ponatinib—Diarrhoea—Vincristine—colon cancer	8.75e-05	0.00104	CcSEcCtD
Ponatinib—Haemorrhage—Methotrexate—colon cancer	8.73e-05	0.00104	CcSEcCtD
Ponatinib—Myalgia—Capecitabine—colon cancer	8.69e-05	0.00104	CcSEcCtD
Ponatinib—Arthralgia—Capecitabine—colon cancer	8.69e-05	0.00104	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	8.63e-05	0.00103	CcSEcCtD
Ponatinib—CYP2D6—liver—colon cancer	8.61e-05	0.00128	CbGeAlD
Ponatinib—Diarrhoea—Irinotecan—colon cancer	8.52e-05	0.00102	CcSEcCtD
Ponatinib—Dry mouth—Capecitabine—colon cancer	8.5e-05	0.00102	CcSEcCtD
Ponatinib—Dizziness—Vincristine—colon cancer	8.46e-05	0.00101	CcSEcCtD
Ponatinib—Pruritus—Fluorouracil—colon cancer	8.44e-05	0.00101	CcSEcCtD
Ponatinib—ABCB1—lymphoid tissue—colon cancer	8.42e-05	0.00126	CbGeAlD
Ponatinib—Visual impairment—Methotrexate—colon cancer	8.42e-05	0.00101	CcSEcCtD
Ponatinib—Oedema—Capecitabine—colon cancer	8.33e-05	0.000995	CcSEcCtD
Ponatinib—ABCB1—digestive system—colon cancer	8.31e-05	0.00124	CbGeAlD
Ponatinib—Infection—Capecitabine—colon cancer	8.28e-05	0.000989	CcSEcCtD
Ponatinib—Dizziness—Irinotecan—colon cancer	8.24e-05	0.000984	CcSEcCtD
Ponatinib—Nervous system disorder—Capecitabine—colon cancer	8.17e-05	0.000976	CcSEcCtD
Ponatinib—Eye disorder—Methotrexate—colon cancer	8.16e-05	0.000975	CcSEcCtD
Ponatinib—Diarrhoea—Fluorouracil—colon cancer	8.16e-05	0.000975	CcSEcCtD
Ponatinib—Thrombocytopenia—Capecitabine—colon cancer	8.16e-05	0.000975	CcSEcCtD
Ponatinib—Vomiting—Vincristine—colon cancer	8.13e-05	0.000971	CcSEcCtD
Ponatinib—Cardiac disorder—Methotrexate—colon cancer	8.11e-05	0.000968	CcSEcCtD
Ponatinib—Skin disorder—Capecitabine—colon cancer	8.1e-05	0.000967	CcSEcCtD
Ponatinib—Rash—Vincristine—colon cancer	8.06e-05	0.000963	CcSEcCtD
Ponatinib—Hyperhidrosis—Capecitabine—colon cancer	8.06e-05	0.000962	CcSEcCtD
Ponatinib—Dermatitis—Vincristine—colon cancer	8.06e-05	0.000962	CcSEcCtD
Ponatinib—Headache—Vincristine—colon cancer	8.01e-05	0.000957	CcSEcCtD
Ponatinib—Angiopathy—Methotrexate—colon cancer	7.92e-05	0.000946	CcSEcCtD
Ponatinib—Vomiting—Irinotecan—colon cancer	7.92e-05	0.000946	CcSEcCtD
Ponatinib—Dizziness—Fluorouracil—colon cancer	7.89e-05	0.000942	CcSEcCtD
Ponatinib—Mediastinal disorder—Methotrexate—colon cancer	7.87e-05	0.00094	CcSEcCtD
Ponatinib—Rash—Irinotecan—colon cancer	7.85e-05	0.000938	CcSEcCtD
Ponatinib—Dermatitis—Irinotecan—colon cancer	7.84e-05	0.000937	CcSEcCtD
Ponatinib—Chills—Methotrexate—colon cancer	7.84e-05	0.000936	CcSEcCtD
Ponatinib—Headache—Irinotecan—colon cancer	7.8e-05	0.000932	CcSEcCtD
Ponatinib—Alopecia—Methotrexate—colon cancer	7.72e-05	0.000922	CcSEcCtD
Ponatinib—ABCB1—bone marrow—colon cancer	7.66e-05	0.00114	CbGeAlD
Ponatinib—Mental disorder—Methotrexate—colon cancer	7.65e-05	0.000914	CcSEcCtD
Ponatinib—Erythema—Methotrexate—colon cancer	7.6e-05	0.000908	CcSEcCtD
Ponatinib—Malnutrition—Methotrexate—colon cancer	7.6e-05	0.000908	CcSEcCtD
Ponatinib—Nausea—Vincristine—colon cancer	7.6e-05	0.000907	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Capecitabine—colon cancer	7.59e-05	0.000907	CcSEcCtD
Ponatinib—Vomiting—Fluorouracil—colon cancer	7.58e-05	0.000906	CcSEcCtD
Ponatinib—Insomnia—Capecitabine—colon cancer	7.54e-05	0.0009	CcSEcCtD
Ponatinib—Rash—Fluorouracil—colon cancer	7.52e-05	0.000898	CcSEcCtD
Ponatinib—Dermatitis—Fluorouracil—colon cancer	7.51e-05	0.000897	CcSEcCtD
Ponatinib—Paraesthesia—Capecitabine—colon cancer	7.48e-05	0.000894	CcSEcCtD
Ponatinib—Headache—Fluorouracil—colon cancer	7.47e-05	0.000892	CcSEcCtD
Ponatinib—Dyspnoea—Capecitabine—colon cancer	7.43e-05	0.000888	CcSEcCtD
Ponatinib—Nausea—Irinotecan—colon cancer	7.4e-05	0.000883	CcSEcCtD
Ponatinib—Back pain—Methotrexate—colon cancer	7.35e-05	0.000878	CcSEcCtD
Ponatinib—ABCB1—vagina—colon cancer	7.34e-05	0.0011	CbGeAlD
Ponatinib—Dyspepsia—Capecitabine—colon cancer	7.34e-05	0.000876	CcSEcCtD
Ponatinib—Decreased appetite—Capecitabine—colon cancer	7.25e-05	0.000865	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Capecitabine—colon cancer	7.2e-05	0.000859	CcSEcCtD
Ponatinib—Fatigue—Capecitabine—colon cancer	7.19e-05	0.000858	CcSEcCtD
Ponatinib—Vision blurred—Methotrexate—colon cancer	7.16e-05	0.000856	CcSEcCtD
Ponatinib—Pain—Capecitabine—colon cancer	7.13e-05	0.000851	CcSEcCtD
Ponatinib—Constipation—Capecitabine—colon cancer	7.13e-05	0.000851	CcSEcCtD
Ponatinib—Nausea—Fluorouracil—colon cancer	7.08e-05	0.000846	CcSEcCtD
Ponatinib—Anaemia—Methotrexate—colon cancer	7.03e-05	0.000839	CcSEcCtD
Ponatinib—Gastrointestinal pain—Capecitabine—colon cancer	6.82e-05	0.000814	CcSEcCtD
Ponatinib—Leukopenia—Methotrexate—colon cancer	6.81e-05	0.000813	CcSEcCtD
Ponatinib—Cough—Methotrexate—colon cancer	6.63e-05	0.000792	CcSEcCtD
Ponatinib—Abdominal pain—Capecitabine—colon cancer	6.59e-05	0.000787	CcSEcCtD
Ponatinib—Body temperature increased—Capecitabine—colon cancer	6.59e-05	0.000787	CcSEcCtD
Ponatinib—Arthralgia—Methotrexate—colon cancer	6.47e-05	0.000773	CcSEcCtD
Ponatinib—Myalgia—Methotrexate—colon cancer	6.47e-05	0.000773	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	6.43e-05	0.000768	CcSEcCtD
Ponatinib—ABCB1—liver—colon cancer	6.19e-05	0.000924	CbGeAlD
Ponatinib—Infection—Methotrexate—colon cancer	6.16e-05	0.000736	CcSEcCtD
Ponatinib—Nervous system disorder—Methotrexate—colon cancer	6.08e-05	0.000727	CcSEcCtD
Ponatinib—Thrombocytopenia—Methotrexate—colon cancer	6.08e-05	0.000726	CcSEcCtD
Ponatinib—Skin disorder—Methotrexate—colon cancer	6.03e-05	0.00072	CcSEcCtD
Ponatinib—Hyperhidrosis—Methotrexate—colon cancer	6e-05	0.000716	CcSEcCtD
Ponatinib—Asthenia—Capecitabine—colon cancer	5.98e-05	0.000714	CcSEcCtD
Ponatinib—Pruritus—Capecitabine—colon cancer	5.9e-05	0.000704	CcSEcCtD
Ponatinib—Diarrhoea—Capecitabine—colon cancer	5.7e-05	0.000681	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Methotrexate—colon cancer	5.65e-05	0.000675	CcSEcCtD
Ponatinib—Insomnia—Methotrexate—colon cancer	5.61e-05	0.00067	CcSEcCtD
Ponatinib—Paraesthesia—Methotrexate—colon cancer	5.57e-05	0.000665	CcSEcCtD
Ponatinib—Dyspnoea—Methotrexate—colon cancer	5.53e-05	0.000661	CcSEcCtD
Ponatinib—Dizziness—Capecitabine—colon cancer	5.51e-05	0.000658	CcSEcCtD
Ponatinib—Dyspepsia—Methotrexate—colon cancer	5.46e-05	0.000652	CcSEcCtD
Ponatinib—Decreased appetite—Methotrexate—colon cancer	5.39e-05	0.000644	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Methotrexate—colon cancer	5.36e-05	0.00064	CcSEcCtD
Ponatinib—Fatigue—Methotrexate—colon cancer	5.35e-05	0.000639	CcSEcCtD
Ponatinib—Pain—Methotrexate—colon cancer	5.31e-05	0.000634	CcSEcCtD
Ponatinib—Vomiting—Capecitabine—colon cancer	5.3e-05	0.000633	CcSEcCtD
Ponatinib—Rash—Capecitabine—colon cancer	5.26e-05	0.000628	CcSEcCtD
Ponatinib—Dermatitis—Capecitabine—colon cancer	5.25e-05	0.000627	CcSEcCtD
Ponatinib—Headache—Capecitabine—colon cancer	5.22e-05	0.000624	CcSEcCtD
Ponatinib—Gastrointestinal pain—Methotrexate—colon cancer	5.07e-05	0.000606	CcSEcCtD
Ponatinib—Nausea—Capecitabine—colon cancer	4.95e-05	0.000591	CcSEcCtD
Ponatinib—Abdominal pain—Methotrexate—colon cancer	4.9e-05	0.000586	CcSEcCtD
Ponatinib—Body temperature increased—Methotrexate—colon cancer	4.9e-05	0.000586	CcSEcCtD
Ponatinib—ABCB1—lymph node—colon cancer	4.75e-05	0.000708	CbGeAlD
Ponatinib—Asthenia—Methotrexate—colon cancer	4.45e-05	0.000532	CcSEcCtD
Ponatinib—Pruritus—Methotrexate—colon cancer	4.39e-05	0.000524	CcSEcCtD
Ponatinib—Diarrhoea—Methotrexate—colon cancer	4.25e-05	0.000507	CcSEcCtD
Ponatinib—Dizziness—Methotrexate—colon cancer	4.1e-05	0.00049	CcSEcCtD
Ponatinib—Vomiting—Methotrexate—colon cancer	3.95e-05	0.000471	CcSEcCtD
Ponatinib—Rash—Methotrexate—colon cancer	3.91e-05	0.000467	CcSEcCtD
Ponatinib—Dermatitis—Methotrexate—colon cancer	3.91e-05	0.000467	CcSEcCtD
Ponatinib—Headache—Methotrexate—colon cancer	3.89e-05	0.000464	CcSEcCtD
Ponatinib—Nausea—Methotrexate—colon cancer	3.69e-05	0.00044	CcSEcCtD
Ponatinib—KDR—Signaling Pathways—TGFB1—colon cancer	3.11e-06	2.73e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CASP3—colon cancer	3.09e-06	2.72e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—CDKN1A—colon cancer	3.08e-06	2.71e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CCND1—colon cancer	3.07e-06	2.7e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—colon cancer	3.06e-06	2.69e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—HRAS—colon cancer	3.05e-06	2.68e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—AKT1—colon cancer	3.05e-06	2.68e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—EGFR—colon cancer	3.05e-06	2.68e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—EGFR—colon cancer	3.05e-06	2.68e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—AKT1—colon cancer	3.04e-06	2.68e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—EGFR—colon cancer	3.04e-06	2.67e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CTNNB1—colon cancer	3.04e-06	2.67e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—PIK3CA—colon cancer	3.04e-06	2.67e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—KRAS—colon cancer	3.03e-06	2.66e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—KRAS—colon cancer	3.02e-06	2.65e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CCND1—colon cancer	3.01e-06	2.65e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—PIK3CA—colon cancer	3.01e-06	2.65e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—APC—colon cancer	3e-06	2.64e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—PIK3CA—colon cancer	3e-06	2.64e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ABCB1—colon cancer	3e-06	2.63e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—AKT1—colon cancer	2.99e-06	2.63e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—HRAS—colon cancer	2.99e-06	2.63e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CTNNB1—colon cancer	2.98e-06	2.62e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—PIK3CA—colon cancer	2.98e-06	2.62e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CDKN1A—colon cancer	2.97e-06	2.61e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—TYMS—colon cancer	2.94e-06	2.59e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TP53—colon cancer	2.94e-06	2.58e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CASP3—colon cancer	2.94e-06	2.58e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—HRAS—colon cancer	2.93e-06	2.58e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—EP300—colon cancer	2.93e-06	2.58e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—HRAS—colon cancer	2.93e-06	2.58e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CASP3—colon cancer	2.93e-06	2.57e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—PIK3CA—colon cancer	2.93e-06	2.57e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—AKT1—colon cancer	2.92e-06	2.57e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—CTNNB1—colon cancer	2.91e-06	2.56e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CDKN1A—colon cancer	2.91e-06	2.56e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FGFR3—colon cancer	2.9e-06	2.55e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PTGS2—colon cancer	2.88e-06	2.54e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—KRAS—colon cancer	2.88e-06	2.53e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—KRAS—colon cancer	2.88e-06	2.53e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—KRAS—colon cancer	2.87e-06	2.52e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CCND1—colon cancer	2.86e-06	2.51e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—SRC—colon cancer	2.85e-06	2.51e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CCND1—colon cancer	2.85e-06	2.51e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—CDKN1A—colon cancer	2.85e-06	2.5e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CTNNB1—colon cancer	2.83e-06	2.49e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—BRAF—colon cancer	2.82e-06	2.48e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CTNNB1—colon cancer	2.82e-06	2.48e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EP300—colon cancer	2.82e-06	2.48e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—HRAS—colon cancer	2.81e-06	2.47e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CTNNB1—colon cancer	2.79e-06	2.46e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—HRAS—colon cancer	2.79e-06	2.45e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—PIK3CA—colon cancer	2.78e-06	2.44e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—HRAS—colon cancer	2.78e-06	2.44e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EP300—colon cancer	2.77e-06	2.44e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—PIK3CA—colon cancer	2.77e-06	2.44e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CDKN1A—colon cancer	2.77e-06	2.43e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—HRAS—colon cancer	2.76e-06	2.43e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CDKN1A—colon cancer	2.76e-06	2.42e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—NRAS—colon cancer	2.75e-06	2.41e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—SRC—colon cancer	2.75e-06	2.41e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CDKN1A—colon cancer	2.73e-06	2.4e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—HRAS—colon cancer	2.71e-06	2.38e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—EP300—colon cancer	2.71e-06	2.38e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—SRC—colon cancer	2.7e-06	2.37e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—AKT1—colon cancer	2.7e-06	2.37e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—VEGFA—colon cancer	2.67e-06	2.35e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—APC—colon cancer	2.66e-06	2.34e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—PIK3CA—colon cancer	2.65e-06	2.33e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—PIK3CA—colon cancer	2.64e-06	2.33e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTGS2—colon cancer	2.64e-06	2.32e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—NRAS—colon cancer	2.64e-06	2.32e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—AKT1—colon cancer	2.64e-06	2.32e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—PIK3CA—colon cancer	2.64e-06	2.32e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—SRC—colon cancer	2.63e-06	2.32e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EP300—colon cancer	2.63e-06	2.31e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—VEGFA—colon cancer	2.63e-06	2.31e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EP300—colon cancer	2.62e-06	2.31e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—EP300—colon cancer	2.6e-06	2.28e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—NRAS—colon cancer	2.59e-06	2.28e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—AKT1—colon cancer	2.59e-06	2.28e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—AKT1—colon cancer	2.59e-06	2.28e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CASP3—colon cancer	2.58e-06	2.27e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CTNNB1—colon cancer	2.58e-06	2.27e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—HRAS—colon cancer	2.57e-06	2.26e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—HRAS—colon cancer	2.56e-06	2.25e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—TYMS—colon cancer	2.56e-06	2.25e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—colon cancer	2.56e-06	2.25e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—SRC—colon cancer	2.56e-06	2.25e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—SRC—colon cancer	2.55e-06	2.24e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—NRAS—colon cancer	2.53e-06	2.23e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CDKN1A—colon cancer	2.52e-06	2.22e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCND1—colon cancer	2.51e-06	2.21e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—EGFR—colon cancer	2.5e-06	2.2e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—BRAF—colon cancer	2.5e-06	2.2e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—VEGFA—colon cancer	2.49e-06	2.19e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CTNNB1—colon cancer	2.49e-06	2.19e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—VEGFA—colon cancer	2.49e-06	2.19e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—AKT1—colon cancer	2.48e-06	2.18e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NRAS—colon cancer	2.46e-06	2.16e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ABCB1—colon cancer	2.46e-06	2.16e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PIK3CA—colon cancer	2.46e-06	2.16e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MYC—colon cancer	2.46e-06	2.16e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—AKT1—colon cancer	2.46e-06	2.16e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NRAS—colon cancer	2.46e-06	2.16e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TGFB1—colon cancer	2.45e-06	2.16e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—AKT1—colon cancer	2.45e-06	2.16e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—HRAS—colon cancer	2.45e-06	2.15e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—HRAS—colon cancer	2.45e-06	2.15e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—HRAS—colon cancer	2.44e-06	2.14e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—AKT1—colon cancer	2.44e-06	2.14e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CDKN1A—colon cancer	2.43e-06	2.14e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—NRAS—colon cancer	2.43e-06	2.14e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—TYMS—colon cancer	2.42e-06	2.12e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MYC—colon cancer	2.42e-06	2.12e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TGFB1—colon cancer	2.41e-06	2.12e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PPARG—colon cancer	2.41e-06	2.12e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EGFR—colon cancer	2.41e-06	2.12e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—EP300—colon cancer	2.4e-06	2.11e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—AKT1—colon cancer	2.39e-06	2.1e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EGFR—colon cancer	2.36e-06	2.08e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—KRAS—colon cancer	2.36e-06	2.08e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—MYC—colon cancer	2.36e-06	2.08e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—TGFB1—colon cancer	2.36e-06	2.07e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EP300—colon cancer	2.31e-06	2.03e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—EGFR—colon cancer	2.31e-06	2.03e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MYC—colon cancer	2.29e-06	2.02e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TGFB1—colon cancer	2.29e-06	2.01e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MYC—colon cancer	2.29e-06	2.01e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TGFB1—colon cancer	2.28e-06	2.01e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KRAS—colon cancer	2.27e-06	2e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—AKT1—colon cancer	2.27e-06	2e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	2.27e-06	1.99e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—AKT1—colon cancer	2.26e-06	1.99e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—SRC—colon cancer	2.25e-06	1.98e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—NRAS—colon cancer	2.24e-06	1.97e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EGFR—colon cancer	2.24e-06	1.97e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EGFR—colon cancer	2.24e-06	1.97e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—KRAS—colon cancer	2.23e-06	1.96e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—EGFR—colon cancer	2.21e-06	1.95e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—EP300—colon cancer	2.2e-06	1.93e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—colon cancer	2.19e-06	1.93e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—KRAS—colon cancer	2.18e-06	1.92e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—PIK3CA—colon cancer	2.17e-06	1.91e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NRAS—colon cancer	2.17e-06	1.9e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—AKT1—colon cancer	2.16e-06	1.9e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AKT1—colon cancer	2.16e-06	1.9e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—AKT1—colon cancer	2.15e-06	1.89e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KRAS—colon cancer	2.12e-06	1.86e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CASP3—colon cancer	2.12e-06	1.86e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KRAS—colon cancer	2.11e-06	1.86e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—KRAS—colon cancer	2.09e-06	1.84e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—MYC—colon cancer	2.09e-06	1.84e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PIK3CA—colon cancer	2.09e-06	1.84e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—TGFB1—colon cancer	2.09e-06	1.83e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PPARG—colon cancer	2.09e-06	1.83e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCND1—colon cancer	2.06e-06	1.81e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PIK3CA—colon cancer	2.05e-06	1.8e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—EGFR—colon cancer	2.04e-06	1.8e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CTNNB1—colon cancer	2.04e-06	1.79e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—colon cancer	2.02e-06	1.78e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MYC—colon cancer	2.02e-06	1.77e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TGFB1—colon cancer	2.01e-06	1.77e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—AKT1—colon cancer	2.01e-06	1.77e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—HRAS—colon cancer	2.01e-06	1.77e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—PIK3CA—colon cancer	2e-06	1.76e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CDKN1A—colon cancer	1.99e-06	1.75e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—colon cancer	1.98e-06	1.74e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EGFR—colon cancer	1.97e-06	1.73e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PIK3CA—colon cancer	1.95e-06	1.71e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PIK3CA—colon cancer	1.94e-06	1.71e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—HRAS—colon cancer	1.93e-06	1.7e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—KRAS—colon cancer	1.93e-06	1.7e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—PIK3CA—colon cancer	1.92e-06	1.69e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—HRAS—colon cancer	1.9e-06	1.67e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EP300—colon cancer	1.9e-06	1.67e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTGS2—colon cancer	1.89e-06	1.66e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—colon cancer	1.88e-06	1.66e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—colon cancer	1.88e-06	1.65e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CASP3—colon cancer	1.87e-06	1.65e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KRAS—colon cancer	1.86e-06	1.64e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—HRAS—colon cancer	1.85e-06	1.63e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SRC—colon cancer	1.85e-06	1.62e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCND1—colon cancer	1.82e-06	1.6e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PPARG—colon cancer	1.82e-06	1.6e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CTNNB1—colon cancer	1.81e-06	1.59e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—HRAS—colon cancer	1.8e-06	1.58e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—colon cancer	1.8e-06	1.58e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—HRAS—colon cancer	1.8e-06	1.58e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—HRAS—colon cancer	1.78e-06	1.56e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NRAS—colon cancer	1.77e-06	1.56e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PIK3CA—colon cancer	1.77e-06	1.56e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—AKT1—colon cancer	1.77e-06	1.56e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CDKN1A—colon cancer	1.77e-06	1.55e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PIK3CA—colon cancer	1.71e-06	1.51e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PPARG—colon cancer	1.71e-06	1.5e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AKT1—colon cancer	1.71e-06	1.5e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EP300—colon cancer	1.68e-06	1.48e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AKT1—colon cancer	1.68e-06	1.47e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—colon cancer	1.66e-06	1.46e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MYC—colon cancer	1.65e-06	1.45e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TGFB1—colon cancer	1.65e-06	1.45e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—HRAS—colon cancer	1.64e-06	1.44e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTGS2—colon cancer	1.64e-06	1.44e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—AKT1—colon cancer	1.64e-06	1.44e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PIK3CA—colon cancer	1.63e-06	1.43e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EGFR—colon cancer	1.62e-06	1.42e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ABCB1—colon cancer	1.61e-06	1.41e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—colon cancer	1.59e-06	1.4e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AKT1—colon cancer	1.59e-06	1.4e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AKT1—colon cancer	1.59e-06	1.39e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HRAS—colon cancer	1.58e-06	1.39e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TYMS—colon cancer	1.58e-06	1.39e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—EP300—colon cancer	1.57e-06	1.38e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NRAS—colon cancer	1.57e-06	1.38e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—AKT1—colon cancer	1.57e-06	1.38e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KRAS—colon cancer	1.53e-06	1.34e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MYC—colon cancer	1.46e-06	1.29e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TGFB1—colon cancer	1.46e-06	1.28e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—AKT1—colon cancer	1.45e-06	1.27e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EGFR—colon cancer	1.43e-06	1.26e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTGS2—colon cancer	1.43e-06	1.26e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CA—colon cancer	1.4e-06	1.23e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AKT1—colon cancer	1.4e-06	1.23e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—EP300—colon cancer	1.36e-06	1.2e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—colon cancer	1.36e-06	1.19e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KRAS—colon cancer	1.35e-06	1.19e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTGS2—colon cancer	1.35e-06	1.18e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—AKT1—colon cancer	1.33e-06	1.17e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HRAS—colon cancer	1.3e-06	1.14e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CA—colon cancer	1.24e-06	1.09e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—colon cancer	1.2e-06	1.06e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—EP300—colon cancer	1.19e-06	1.04e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CA—colon cancer	1.17e-06	1.02e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HRAS—colon cancer	1.15e-06	1.01e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AKT1—colon cancer	1.15e-06	1.01e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—EP300—colon cancer	1.12e-06	9.85e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PPARG—colon cancer	1.12e-06	9.84e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AKT1—colon cancer	1.02e-06	8.92e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CA—colon cancer	1.01e-06	8.87e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AKT1—colon cancer	9.52e-07	8.37e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS2—colon cancer	8.8e-07	7.74e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CA—colon cancer	8.79e-07	7.73e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CA—colon cancer	8.28e-07	7.28e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AKT1—colon cancer	8.24e-07	7.25e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—EP300—colon cancer	7.32e-07	6.44e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AKT1—colon cancer	7.18e-07	6.31e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AKT1—colon cancer	6.77e-07	5.95e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CA—colon cancer	5.42e-07	4.76e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AKT1—colon cancer	4.42e-07	3.89e-06	CbGpPWpGaD
